Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute…
| Periodo | 2026-07 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.07 | $0.07 | $0.01 |
| Estimado | $0.06 | — | $0.01 | — |
| Sorpresa | — | — | +600.0% | — |
| Métrica | PHAR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 87.9% | 57.4% | +30.5% |
| Operating Margin | 6.9% | -34.4% | +41.3% |
| Net Margin | 0.8% | -32.5% | +33.2% |
| FCF Margin | 14.3% | -12.6% | +26.9% |
| ROE | 1.0% | -39.2% | +40.2% |
| ROA | 0.6% | -30.9% | +31.5% |
| Current Ratio | 2.59 | 2.73 | -0.14 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 0.6% | — |
| ✓Flujo de caja operativo positivo | $55M | −$2M |
| ✓Rentabilidad sobre activos al alza | 0.6% | -3.0% |
| ✓Caja operativa/activos supera al ROA | 10.9% | ROA 0.6% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 2.59 | 3.77 |
| ✓Sin aumentar el nº de acciones | 747M | 785M |
| ✗Margen bruto al alza | 87.9% | 88.1% |
| ✓Rotación de activos al alza | 0.75 | 0.74 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 14.3% |
| ✗ROCE > 10 % | 6.7% |
| ✓Ventas > 5 %/año (3 años) | 22.3% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 26.9% |
Pharming Group N.V. cotiza a 9.36 USD y tiene una capitalización bursátil de $662M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud